Biocon

Biocon starts clinical study to evaluate efficacy of itolozumab
Biocon Q4: Consolidated revenue growth recorded at Rs 2,476 crore
Biocon, Mylan may merge biosimilar business: Report
Biocon consolidated net profit dips 18 pc to Rs 138 cr in Q2
Nations need to have science-based leadership to deal with pandemic: Mazumdar-Shaw backs Swaminathan
Biocon case: Sebi bans 6 entities for 2 yrs for manipulative trades
Read More
logo
DT next
www.dtnext.in